Abstract

INTRODUCTION AND OBJECTIVES: This study aimed to identify the value of RUNX3 methylation in normal adjacent urothelium of the patients with non-muscle invasive bladder cancer NMIBC). METHODS: Fifty-five tumor tissues and normal donor-matched adjacent tissues from patients underwent transurethral resection (TUR) were selected. RUNX3 promoter methylation was assessed using methylation-specific polymerase chain reaction (MS-PCR). RESULTS: Methylation rate of RUNX3 in normal adjacent urothelium was 47.3%. Promoter methylation occurred frequently in both pathologically normal urothelium and tumor samples from NMIBC patients, and correlated with the transition from normal to bladder tumor (P 0.020). Methylation in normal adjacent urothelium was associated with tumor number (P 0.022) and progression (P 0.035). KaplanMeier estimates revealed that RUNX3 methylation of normal urothelium was associated with significant differences in time to progression (P 0.017) in NMIBC. Multivariate Cox regression analysis showed that RUNX3 methylation in normal urothelium [hazards ratio (HR): 5.692, P 0.042] was an independent predictor of recurrence. CONCLUSIONS: In patients with NMIBC after TUR, RUNX3 methylation in normal adjacent urotehlium predict the disease progression exactly.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call